School of Medicine
Showing 11-20 of 35 Results
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406 -
Kathy Johnson
Executive Administrator, SPARK at Stanford
Current Role at StanfordProgram Administrator, SPARK at Stanford
Executive Admin to:
Daria Mochly-Rosen, Professor
Kevin V. Grimes, Professor - Teaching
Department of Chemical & Systems Biology -
Sharada Kalanidhi
Director of Data Science, Biochemistry - Genome Center
Current Role at StanfordParaphrasing the mathematician Alexander Grothendieck: the essential thing is to pose problems in the right framework.
Sharada is developing a new field, Mathematical Medicine, which applies pure mathematical frameworks to genomic and multi-omic data for quantitative, personalized diagnosis. This approach explores alternatives to prevailing cohort-based statistical paradigms, particularly in complex clinical cases that have resisted standard methods.
After more than a decade of research and close collaboration with biochemists at the Stanford Genome Technology Center (Dept. of Biochemistry), Sharada concluded that the mathematics currently used for multi-omic diagnosis is inadequate for the level of biological and clinical complexity being attempted. Her conclusion echoes the perspective of the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.” Mathematical Medicine represents one possible construction of such an area. This approach is aligned in spirit with the philosophy of the late mathematician Jim Simons: "We don't start with models. We start with data. We don't have any preconceived notions." Mathematical Medicine lets the data speak for itself.
This field is focused on the development of an intermediate translation layer between cohort-based statistical models and individualized multi-omic diagnosis and clinical decision-making. Without this mathematical layer, the clinical adoption of multi-omic data- particularly for complex cases- has been limited. As a result, many complex, multi-system conditions remain undiagnosed or misdiagnosed for long periods, delaying effective treatment and, in some cases, allowing disease processes to worsen. Additionally, what is learned from rare and extreme cases proves highly informative for the rest of the population.
Further information on this field, including opportunities for early philanthropic partnerships, is available at: https://mathmed-2026.web.app/ -
Devanish Narasimhasanth Kamtam
Visiting Instructor, Cardiothoracic Surgery - Thoracic Surgery
BioDr. Devanish Kamtam is a Visiting Instructor in the Division of Thoracic Surgery at Stanford University, working in Dr. Joseph Shrager's lab. His research focuses on surgical AI, AI in medical imaging, and clinical outcomes in Thoracic Surgery. He completed his MBBS at Gandhi Medical College, Hyderabad and MS in General Surgery at AIIMS New Delhi.
-
Jeewon Sylvia Kim
Program Manager, SPARK at Stanford
Current Role at StanfordProgram manager for SPARK Translational Science Program overseeing educational seminar series, managing projects and facilitating SPARK global operations.
-
Bruce Koch, Ph.D.
Senior Research Scientist-Basic Life, Sarafan ChEM-H
Current Role at StanfordDirector, ChEM-H/CSB High Throughput Screening Group
Staff Lead, IMA HTS Module
Adviser to the SPARK Program -
Joanna E. Liliental, PhD
Director, TRAM, M-TRAM, TASC, Med/TRAM
Current Role at StanfordExecutive Director, Master's in TRAM (M-TRAM)
https://med.stanford.edu/tram/masters-program.html
Director, Translational Applications Service Center (TASC)
http://tasc.stanford.edu
Associate Director, Translational Research and Applied Medicine (TRAM) Program
http://tram.stanford.edu
Senior Research Scientist, Stanford School of Medicine
Instructor of University Courses: MED221,MED121, MED212A
Member, Stanford Cancer Institute -
Xin Liu
Basic Life Science Research Scientist, Genetics
BioXin Liu is a postdoctoral Research Scientist in the Department of Genetics at Stanford University. Xin holds a PhD in Chemistry from the University of Michigan, Ann Arbor. Her basic research interests include RNA and protein biochemistry, enzymology, cancer immunology, and autoimmune disease. She has published papers in several prestigious journals in the field of biochemistry, including Nature Communications, Journal of American Chemical Society, and Nucleic Acids Research. The highlight of her multidisciplinary research includes the development of high-throughput enzymatic methods to discover anti-microbial agents and to reveal mechanisms behind human mitochondrial diseases, as well as innovative applications of genome engineering and machine-learning to decode principles of RNA editing in human cells. Her current research focuses on the mechanistic study of innate immune pathways.
